Company is aiming to apply for FDA approval by March next year.
Lecanemab, a drug developed by the Japanese pharmaceutical company, Eisai Co. Ltd has shown promising results in a clinical trial by slowing cognitive decline in Alzheimer's patients who received it,. This is the first drug to blunt the progression of the symptom in the final-phase trial so far.
Tokyo-based Eisai has developed the drug with Massachusetts-based Biogen Inc. and is the second drug the collaboration has developed to lower amyloid, a toxic protein that is found in the brains of patients with Alzheimer's disease.Multiple pharmaceutical companies have attempted to develop drugs that can reduce amyloid in the brain. However, clinical trials, including one for Aduhelm, developed by Eisai and Biogen, haveThe study conducted at sites in Japan, China, Europe, and the U.S.
Participants in the study were allocated in 1:1 ratio to receive either the placebo or the drug, lecanemab. Patients in the treatment group were bi-weekly administered 10mg of each kg of body weight for a period of 18 months. When compared on a common rating scale, the drug-treated group was observed to have slowed cognitive decline in the patients by 27 percent, also compared to the placebo group, aThis is not only a significant result, but it also confirms the amyloid hypothesis for the disease progression that has come under lens after years of failed trials.Lecanemab is a monoclonal antibody that binds to neutralize and eliminate the amyloid-beta aggregates in the brain.
Prior to doing that, the full results of the study are expected to be published at a medical conference next month, following which a scientific publication is also expected,
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Read more »
Alzheimer's drug slowed progression of the disease in Phase 3 trialThe Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness.
Read more »
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Read more »
Alzheimer's-slowing drug labelled historicThe drug appears to reduce the pace of the disease, in early data from clinical trials.
Read more »
Analysis: Alzheimer's drug trial breakthrough boost for Roche, Eli LillyThe results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.
Read more »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Read more »